Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signalling

Despite initial progress in preclinical models, most known histone deacetylase inhibitors (HDACis) used as a single agent have failed to show clinical benefits in nearly all types of solid tumours. Hence, the efficacy of HDACis in solid tumours remains uncertain. Herein, we developed a hybrid HDAC i...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Zhi, Zhou, Wei, Li, Yongtao, Cao, Mei, Wang, Tianqi, Ma, Yakun, Guo, Qingxiang, Wang, Xin, Zhang, Chao, Zhang, Chenglan, Shen, Wenzhi, Liu, Yanhua, Chen, Yanan, Zheng, Jianyu, Yang, Shengyong, Fan, Yan, Xiang, Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6217055/
https://www.ncbi.nlm.nih.gov/pubmed/30429882
http://dx.doi.org/10.7150/thno.26627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6217055/
https://www.ncbi.nlm.nih.gov/pubmed/30429882
http://dx.doi.org/10.7150/thno.26627

Ejemplares similares